Phase II double blinded randomized placebo-controlled trial of minocycline to ameliorate chemotherapy-induced cognitive changes in breast cancer (BC) patients.
Sharpe J, Schnell P, Knopp M, Binzel K, Magyer M, Cherian M, Gatti-Mays M, Pariser A, Wesolowski R, Sardesai S, VanDeusen J, Stover D, Ramaswamy B, Williams N, DeVries A, Shinde N, Orchard T, Lustberg M. Phase II double blinded randomized placebo-controlled trial of minocycline to ameliorate chemotherapy-induced cognitive changes in breast cancer (BC) patients. Journal Of Clinical Oncology 2021, 39: e12528-e12528. DOI: 10.1200/jco.2021.39.15_suppl.e12528.Peer-Reviewed Original ResearchPET/CT imagingPET/CTCytokine levelsMicroglial activationCT imagingF-fluorodeoxyglucoseDouble-blinded randomized placebo-controlled trialBlinded randomized placebo-controlled trialChemotherapy-induced cognitive changesRandomized placebo-controlled trialCognitive functionPlacebo-controlled trialInflammatory cytokine levelsBreast cancer patientsCognitive changesCT brain imagingAC therapyDaily minocyclinePotent mitigatorNeoadjuvant chemotherapyPlacebo groupInflammatory markersInflammatory changesMedian ageMinocycline group
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply